Avacta Group PLC Avacta to Present at BioTrinity 2017
02 May 2017 - 4:02PM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
02 May 2017
2 May 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at BioTrinity 2017
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, is pleased to announce that
its Chief Executive, Alastair Smith, will be presenting at
BioTrinity 2017, Europe's leading Biopartnering and Investment
Conference, to be held on 9-10 May at the Novotel London West.
Founded and produced by OBN, BioTrinity is now in its 11(th)
year. BioTrinity continues to grow with more than 1000 senior
executives and decision makers from emerging and established
companies across the life sciences sector and investment firms
expected to attend.
Avacta's Chief Executive, Alastair Smith, will be presenting in
the Company Showcase Therapeutics Track at 1440 in the Alsace Room.
The Company will also be exhibiting at stand 44.
ENDS
NOTES
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0)
WG Partners 203 705 9318
Nigel Birks / Nigel Barnes Tel: +44 (0)
David Wilson / Claes Spang 203 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Tel: +44 (0)7787
Regional Media) 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
FTI Consulting (Financial Media Tel: +44 (0)
and IR) 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Affimer technology has been designed to address many of the
negative performance issues of antibodies, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
About OBN
OBN is the Membership organisation supporting and bringing
together the UK's innovative life sciences companies, corporate
partners and investors. Our 400-plus member companies are located
across the Golden Triangle and beyond to Nottingham, Manchester and
Scotland and benefit from our networking, partnering, purchasing,
advising and advocacy activities. OBN is best known for its
delivery of BioTrinity (11th edition: May 9-10, 2017), Europe's
leading life sciences investment and biopartnering conference,
visit www.biotrinity.com for more information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKKDBKBKBKQN
(END) Dow Jones Newswires
May 02, 2017 02:01 ET (06:01 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024